For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
November 24, 2016
- MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
- MHLW to Revise Rules on Development Requests for Unapproved Drugs
November 22, 2016
- Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
November 22, 2016
- MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
November 21, 2016
- MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
November 18, 2016
- MOF Panel Budget Recommendation Calls for Curbing Drug Costs
November 18, 2016
- 10 APIs/17 Products to Join NHI Price List on Nov. 18
November 17, 2016
- Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
November 17, 2016
- Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
November 17, 2016
- 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
November 17, 2016
- ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
November 16, 2016
- 3 Immunosuppressants to Be Discussed for Lifting of Contraindicated Pregnancy Use
November 16, 2016
- Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
November 15, 2016
- MHLW Advisory Committee to Review Biogen’s MS Drug on Nov. 25
November 14, 2016
- Opdivo Gets MHLW Panel Nod for Hodgkin’s Lymphoma
November 14, 2016
- MHLW Panel to Discuss NSCLC Indication for Keytruda on Nov. 24
November 14, 2016
- LDP Study Group on Biologics to Hold 1st Meeting on Nov. 24; Aims to Halt the Rush to Promote Biosimilars
November 11, 2016
- Chuikyo Members Chide Unexplained Withdrawal of Taltz’s Listing Request
November 10, 2016
- MHLW Won’t Require Use of Other Psoriasis Drugs before Taltz
November 10, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…